In the last trading session, 3.76 million shares of the Intellia Therapeutics Inc (NASDAQ:NTLA) were traded, and its beta was 1.77. Most recently the company’s share price was $15.95, and it changed around $0.1 or 0.63% from the last close, which brings the market valuation of the company to $1.62B. NTLA currently trades at a discount to its 52-week high of $34.87, offering almost -118.62% off that amount. The share price’s 52-week low was $15.35, which indicates that the current value has risen by an impressive 3.76% since then. We note from Intellia Therapeutics Inc’s average daily trading volume that its 10-day average is 3.06 million shares, with the 3-month average coming to 1.62 million.
Intellia Therapeutics Inc stock received a consensus recommendation rating of Overweight, based on a mean score of 1.50. If we narrow it down even further, the data shows that 0 out of 6 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 2 recommended NTLA as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight. Intellia Therapeutics Inc is expected to report earnings per share of -1.38 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Intellia Therapeutics Inc (NASDAQ:NTLA) trade information
Instantly NTLA has showed a green trend with a performance of 0.63% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 21.17 on recent trading dayincreased the stock’s daily price by 24.66%. The company’s shares are currently down -47.69% year-to-date, but still down -24.34% over the last five days. On the other hand, Intellia Therapeutics Inc (NASDAQ:NTLA) is -22.46% down in the 30-day period. We can see from the shorts that 16.36 million shares have been sold at a short interest cover period of 9.55 day(s).
The consensus price target as assigned by Wall Street analysts is $109, which translates to bulls needing to increase their stock price by 85.37% from its current value. Analyst projections state that NTLA is forecast to be at a low of $18 and a high of $252.
Intellia Therapeutics Inc (NTLA) estimates and forecasts
Intellia Therapeutics Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -23.17 percent over the past six months and at a -0.74% annual growth rate that is well below the industry average of 17.50%. The year-over-year growth rate is expected to be 46.40%, up from the previous year.
Consensus estimates provided by 21 financial analysts predict the company will bring in an average of 7.86M in revenue for the current quarter. 21 analysts expect Intellia Therapeutics Inc to make 8.63M in revenue for the current ending quarter. Forecasts for the next quarter put sales growth at -550.20%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -22.30%. Intellia Therapeutics Inc earnings are expected to increase by -0.04% in 2024, but the outlook is positive 30.00% per year for the next five years.
NTLA Dividends
Intellia Therapeutics Inc’s next quarterly earnings report is expected to be released in November.
Intellia Therapeutics Inc (NASDAQ:NTLA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.21% of Intellia Therapeutics Inc shares, and 87.20% of them are in the hands of institutional investors. The stock currently has a share float of 88.27%. Intellia Therapeutics Inc stock is held by 419.0 institutions, with ARK INVESTMENT MANAGEMENT LLC being the largest institutional investor. By 2024-06-30, it held 12.1419% of the shares, which is about 11.6 million shares worth $259.51 million.
BLACKROCK INC., with 10.0496% or 9.6 million shares worth $214.79 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
